Heart Attacks
main-banner
Heart Attacks
CSL112_3001 Enrolling

Heart Attack Research Study (12 Months)


Age: 18 Years


Official Title

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome

ClinicalTrials.gov ID

NCT03473223

Sponsor

CSL Behring

Study Description

  • Brief Summary:

    CSL Behring

  • Condition or Disease:

    Acute Coronary Syndrome

  • Intervention/Treatment:

    Biological: Apolipoprotein A-I [human] (apoA-I) Other: Placebo
  • Phase:

    Phase 3

  • Ages Eligible for Study:

    18 Years and older (Adult,Older Adult)

  • Sexes Eligible for Study:

    All

Inclusion Criteria:

Male or female least 18 years of age
Evidence of myocardial necrosis, consistent with type I (spontaneous) MI
No suspicion of acute kidney injury
Evidence of multivessel coronary artery disease

Presence of established cardiovascular risk factor(s):

Diabetes mellitus on pharmacotherapy OR
2 or more of the following: age ≥ 65 years, prior history of MI, peripheral arterial disease

Exclusion Criteria:

Ongoing hemodynamic instability
Evidence of hepatobiliary disease
Evidence of severe chronic kidney disease
Plan to undergo scheduled coronary artery bypass graft surgery as treatment for the index MI
Known history of allergies, hypersensitivity, or deficiencies to soy bean, peanut or albumin


Participating Locations

COUNTRY
country-icon
Canada

Participating Experts

Dr. Michael Hartleib, MSc, MD, FRCPC

Cardiologist

You May Also Be Interested In

Similar Trials

No Similar Trials Found
about-icon

Learn More About

Heart Attacks

Learn More
2022 all rights reserved probity medical research inc
find a trial
filter trials

Filter By Keyword

Trial Name, Intervention and or Treatment, Trial Number, Reference Number, Study Info, Sponsors Phase, and Status.